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Size-dependent inhibitory effects of antibiotic
nanocarriers on filamentation of E. coli
Preeyaporn Songkiatisak, † Feng Ding, † Pavan Kumar Cherukuri†
and Xiao-Hong Nancy Xu *
Multidrug membrane transporters exist in both prokaryotic and eukaryotic cells and cause multidrug
resistance (MDR), which results in an urgent need for new and more effective therapeutic agents. In this
study, we used three different sized antibiotic nanocarriers to study their mode of action and their size-
dependent inhibitory effects against Escherichia coli (E. coli). Antibiotic nanocarriers (AgMUNH–Oflx NPs)
with 8.6  102, 9.4  103 and 6.5  105 Oflx molecules per nanoparticle (NP) were prepared by
functionalizing Ag NPs (2.4  0.7, 13.0  3.1 and 92.6  4.4 nm) with a monolayer of 11-amino-1-
undecanethiol (MUNH2) and covalently linking ofloxacin (Oflx) with the amine group of AgMUNH2 NPs,
respectively. We designed a modified cell culture medium for nanocarriers to be stable (non-aggregated)
over 18 h of cell culture, which enabled us to quantitatively study their size and dose dependent
inhibitory effects against E. coli. We found that the inhibitory effects of Oflx against E. coli highly
depended upon the dose of Oflx and the size of the nanocarriers, showing that an equal amount of Oflx
that was delivered by the largest nanocarriers (92.6  4.4 nm) were most potent with the lowest
minimum inhibitory concentration (MIC50) and created the longest and highest percentage of
filamentous cells, while the smallest nanocarriers (2.4  0.7) were least potent with the highest MIC50
and produced the shortest and lowest percentage of filamentous cells. Interestingly, the same amount of
Oflx on 2.4  0.7 nm nanocarriers showed a 2 higher MIC and created 2 shorter filamentous cells
than free Oflx, while the Oflx on 13.0  3.1 and 92.6  4.4 nm nanocarriers exhibited 2 and 6 lower
MICs, and produced 2 and 3 longer filamentous cells than free Oflx, respectively. Notably, the three
different sized AgMUNH2 NPs (absence of Oflx) showed negligible inhibitory effects and did not create
filamentous cells. The results show that the filamentation of E. coli highly depends upon the sizes of
nanocarriers, which leads to the size-dependent inhibitory effects of nanocarriers against E. coli.
Introduction
Antibiotics have been widely used to treat infectious diseases for
years. Multi-antibiotic resistance has led to ineffectiveness of
conventional antibiotics, creation of super bugs and an urgent
need for new antibiotics to treat infectious diseases. Multidrug
membrane transporters exist in both prokaryotes and eukary-
otes, and they can selectively extrude structurally and func-
tionally unrelated substrates out of the cells to keep the
intracellular drug concentration low, which leads to low efficacy
of therapeutic agents.1–6 Thus, multidrug membrane trans-
porters have been extensively studied over decades and they
have been selected as drug targets to overcome MDR and
improve the efficacy of therapeutic drugs. However, despite
extensive studies, molecular mechanisms and functions of
multidrug membrane transporters remain elusive.7,8
Escherichia coli (E. coli) is a Gram-negative bacterium and can
cause severe diarrhea, urinary tract infections and respiratory
illness.9,10 There are several multidrug membrane transporters
in E. coli.11–13 For instance, the MsbA in E. coli is a well-known
multidrug ATP-binding cassette (ABC) transporter that is closely
related to other multidrug membrane transporters (e.g., Pgp,
ABCB1, and MDR1) in eukaryotes.11–13 MsbA shares a common
modular architecture with other ABC transporters and consists
of two transmembrane domains (TMDs) that dene substrate
binding-sites and form the transport passageway for substrates
to cross the cellular membrane, and two nucleotide-binding
domains (NBDs) that bind and hydrolyze ATP to provide the
“power-stroke” for the transporter to translocate specic
substrates across the cellular membrane.14–20 Studies have
shown that MsbA uses both ATP and proton gradients across
the cellular membrane as energy sources to extrude pump
substrates out of cells.21
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Extensive efforts have been made to study and overcome
MDR mediated by multidrug efflux pumps. Polymer-based NPs
have been used to increase the drug payload and to increase the
efficacy of therapeutic agents.22–25 Other NPs themselves have
showed inhibitory effects against bacteria.26,27 However, the
dependence of their efficacy and inhibitory effects upon their
physicochemical properties has not yet been systematically
studied, which hinders rational design of drug nanocarriers to
effectively overcome MDR and to effectively achieve their
maximum efficacy. Noble metal NPs (e.g. Ag and Au NPs)
possess distinctive plasmonic optical properties, superior
photostability and well characterized size, shape and surface
properties. Thus, they can serve as a model system to study the
size-dependent inhibitory effects of drug nanocarriers and
serve as imaging probes to track their distributions and study
their mode of actions against cells. We have demonstrated that
we can image and characterize the sizes of single Ag NPs at
nanometer (nm) resolution in single live cells in situ in real
time using size-dependent localized surface plasmon reso-
nance (LSPR) spectra of single Ag NPs by dark-eld optical
microscopy and spectroscopy (DFOMS).28–44 We have used the
size-dependent LSPR spectra of single Ag NPs to track the
transport of single NPs in and out of single live cells and to
determine the pore sizes of membrane transporters.29,30
In our previous studies, we found dose and size dependent
inhibitory effects of antibiotic nanocarriers (AgMUNH–Ox
NPs) against Pseudomonas aeruginosa (Gram-negative bacte-
rium) and Bacillus subtilis (Gram-positive bacterium).45,46 Inter-
estingly, we found that inhibitory effects of antibiotic
nanocarriers highly depended upon the expression of MexAB-
OprM (a multidrug ABC membrane transporter in Pseudomonas
aeruginosa),46 but not the expression of BmrA (a multidrug
membrane transporter) in Bacillus subtilis.45 In this study, we
used the exactly same antibiotic nanocarriers to study the dose
and size dependent inhibitory effects of nanocarriers against E.
coli (Gram-negative bacterium), and used an ATPase inhibitor
(orthovanadate) to inhibit ABC transporters in E. coli, aiming to
study the mode of action of nanocarriers and the dependence of
inhibitory effects of nanocarriers upon ABC transporters and
the bacterial strain.
Materials and methods
Reagents and the cell line
Silver nitrate (99.9%), sodium citrate dehydrate (99%), sodium
borohydride (98%), hydrogen peroxide (30%), poly-
vinylpyrrolidone (PVP), 2-mercaptoethanol (99%), 11-amino-1-
undecanethiol hydrochloride (MUNH2, 99%), ooxacin powder
(99%), orthovanadate ($90%), sodium chloride, sodium phos-
phate, sodium phosphate monobasic monohydrate, Bacto-
Tryptone, and Bacto Yeast Extract were purchased from Sigma-
Aldrich. N-Hydroxysulfosuccinimide (Sulfo-NHS, 98.5%,
Pierce), 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide
hydrochloride (EDC, 99%, Pierce), silver perchlorate mono-
hydrate (99%, Alfa Aesar), live/dead backlight viability assay
(Life Technologies), and Hoechst 33342 (Life Technologies)
were purchased as indicated, and used as received. The cell line
of Escherichia coli (wt w3110) was purchased from a genetic
stock center (CGSC). Deionized (DI) water (18 MU water, Barn-
stead) was used to prepare all the solutions including a stan-
dard LB medium (1% tryptone peptone, 0.5% yeast extract, and
0.5% NaCl, pH ¼ 7.2) and a modied LB medium (1% tryptone
peptone, 0.5% yeast extract, and 0.1% NaCl, pH ¼ 7.2).
Synthesis and characterization of antibiotic nanocarriers
We synthesized, puried and characterized three different sized
antibiotic nanocarriers with diameters of Ag NPs of (2.4  0.7),
(13.0  3.1) and (92.6  4.4) nm and the molar conjugation
ratios of antibiotics (Ox) per NP of 8.6 102, 9.4 103, and 6.5
 105, respectively, as we reported previously.46 We rst
synthesized, puried and characterized the three different sized
Ag NPs, as we reported previously.28,30,34,37,47,48 We characterized
the NP concentrations, the plasmonic optical properties (LSPR
images and spectra), sizes and zeta potentials of single NPs
using UV-Vis absorption spectroscopy (Hitachi U-2010), dark-
eld optical microscopy and spectroscopy (DFOMS), high-
resolution transmission electron microscopy (HRTEM) (JEOL,
JEM-2100F), and dynamic light scattering (DLS) (Nicomp
380ZLS particle sizing system), respectively.28,30,34,37,47,48
We used the interaction of thiol groups of MUNH2 with the
NPs to directly attach 11-amino-1-undecanethiol hydrochloride
(MUNH2) onto the surface of NPs and create AgMUNH2 NPs.46
We removed excess MUNH2 by thoroughly washing the
AgMUNH2 NPs with DI water three times using centrifugation
(Beckman Optima L90k, 4 C). We then covalently conjugated
the carboxyl group of Ox with the amine groups of MUNH2
attached onto the surface of the NPs (AgMUNH2 NPs) via the
peptide bond to prepare antibiotic nanocarriers (AgMUNH–Ox
NPs) using a two-step method via EDC and s-NHS as mediators
(Fig. 1). We thoroughly washed the drug nanocarriers with DI
water three times and stored them at 4 C for future use.
We characterized the concentrations, optical properties
and sizes of the nanocarriers using UV-Vis absorption
spectroscopy, DFOMS and DLS, respectively. We determined
the molar concentration of NPs and Ox attached on the NPs
for each different sized nanocarrier by measuring the plas-
monic absorption spectra of the NPs and the absorbance
spectra of Ox at 288 nm, respectively.46 We then divided the
molar concentrations of Ox molecules on the surface of the
nanocarriers by the molar concentration of the NPs, to
determine the molar conjugation ratios of Ox molecules/
NP for each different sized nanocarrier. We studied the
stability of each different sized nanocarrier (AgMUNH–Ox
NPs) in the standard (1% tryptone peptone, 0.5% yeast
extract, and 0.5% NaCl, pH ¼ 7.2) and modied LB medium
(1% tryptone peptone, 0.5% yeast extract, and 0.1% NaCl, pH
¼ 7.2) over 24 h using UV-Vis absorption spectra, DLS and
DFOMS.
Design of the cell culture medium and characterization of
cultured cells
We studied the cell growth of the E. coli strain in the standard
and the modied LB medium in parallel. We rst pre-cultured


































































































the cells in a standard LB medium in a oor shaker (Thermo
Scientic, MaxQ5000) (200 rpm, 37 C) for 12 h. We then
cultured the cells in either the standard LB medium or the
modied LB medium in the shaker (200 rpm, 37 C) for another
8 h. We followed the cell growth in each medium over time and
characterized the cell growth curves by measuring OD600 nm of
the cell suspension every 6 h over 18 h (Fig. 2). The cell
suspension was diluted 10 and measured with an OD600 nm
below 0.25, in order to ensure that the cell concentration can be
determined using OD600 nm. Finally, by the end of cell culture at
18 h, we characterized the viability of the cultured cells at single-
cell resolution using live/dead BacLight viability and counting
assay (Fig. 3).49 We imaged the cells in a micro-chamber using
dark-eld optical microscopy and epi-uorescence microscopy
and counted the green uorescent cells (peak wavelength of
uorescence spectra of SYTO9, lmax ¼ 520 nm) and the red
uorescent cells (peak wavelength of uorescence spectra of
propidium iodide, lmax ¼ 610 nm) as live and dead cells,
respectively.29,44,46,49
We further characterized the efflux function of the ABC
membrane transporter of the cells cultured in the standard
and the modied LB medium by measuring the time-course of
the uorescence intensity of the dye (Hoechst 33342) accu-
mulated inside the cells in the presence and absence of the
ATPase inhibitor (orthovanadate) using uorescence spec-
troscopy, as described in the following.29,50,51 We harvested the
cultured cells using centrifugation (Beckman Model J2-21
Centrifuge, JA-14 rotor, at 7500 rpm, 23 C, 10 min), thor-
oughly washed the cells with the PBS buffer (0.5 mM phos-
phate buffer, 1.5 mM NaCl, pH 7.2) three times, and re-
suspended the cells in the buffer. The nal concentration of
the cells was adjusted to OD600 nm ¼ 0.1. The time-course
uorescence intensity of Hoechst 33342 (0.5 mM) incubated
with the cells in the presence and absence of orthovanadate
(25 mM) was measured at a 10 s data acquisition interval in
real time using a uorescence spectrometer (PerkinElmer
LS50B) (Fig. 4). The excitation and emission wavelengths were
354 and 478 nm, respectively.
Fig. 1 Chemical reactions of synthesis of antibiotic nanocarriers. Functionalization of Ag NPs with a self-assembled monolayer of 11-amino-1-
undecanethiol (MUNH2) by interaction of its thiol groups (–SH) with the surface of Ag NPs with diameters of (A) 2.4  0.7, (B) 13.0  3.1 and (C)
92.6  4.4 nm to synthesize AgMUNH2 NPs. The amine groups of AgMUNH2 NPs were covalently conjugated with the carboxyl groups of
ofloxacin (Oflx) via the peptide bond using EDC and sulfo-NHS as mediators to produce AgMUNH–Oflx NPs, which we named as antibiotic
nanocarriers.46
Fig. 2 Study of the growth kinetics of the live cells (E. coli) cultured in
(A) standard and (B) modified LB medium. The cell growth curves of E.
coli in the (A) standard and (B) modified LB medium show that the
growth rates of the cells cultured in either medium are nearly identical,
which indicates that the cells in the modified LB medium grew nor-
mally. Each cell suspension was diluted 10 and measured at OD600
nm below 0.25.


































































































Study of size-dependent inhibitory effects of antibiotic
nanocarriers against E. coli
We cultured the cells (104 pre-cultured cells) in the modied LB
medium (3.0 mL) containing a dilution series of free Ox and
Ox attached onto the given sized drug nanocarrier in a shaker
(MaxQ5000) under vigorous shaking (200 rpm, 37 C) over 18 h.
The dilution series consist of (a) 0, (b) 0.045, (c) 0.09, (d) 0.18, (e)
0.38, and (f) 0.68 mM free Ox (Fig. 5A(a–f)) or the same
concentrations of Ox attached onto the nanocarriers which
correspond to the concentrations of (Fig. 5B): (a) 0.79 nM
AgMUNH2 NPs (in the absence of Ox, control), and
nanocarriers (NP concentrations): (b) 5.2  102, (c) 0.10, (d)
0.21, (e) 0.44, and (f) 0.79 nM for 2.4  0.7 nm NPs with a molar
conjugation ratio of 8.6  102 Ox molecules per NP; (Fig. 5C):
(a) 7.2  102 nM AgMUNH2 NPs (in the absence of Ox,
control), and nanocarriers (NP concentrations): (b) 4.8  103,
(c) 9.5  103, (d) 1.9  102, (e) 4.0  102, and (f) 7.2  102
nM for 13.0  3.1 nm NPs with a molar conjugation ratio of 9.4
 103 Ox molecules per NP; and (Fig. 5D): (a) 1.0 pM AgMUNH2
NPs (in the absence of Ox, control), and nanocarriers (NP
concentrations): (b) 6.9  102, (c) 0.14, (d) 0.28, (e) 0.58, and (f)
1.0 pM for 92.6  4.4 nm NPs with a molar conjugation ratio of
6.5  105 Ox molecules per NP. The experiments and controls
were carried out in parallel and under the same conditions.
We sampled the cell suspensions every 6 h, diluted each
suspension 10 using the medium and then quantitatively
determined the bacterial cell concentration by measuring the
optical density at 600 nm (OD600 nm) in a 96-well plate using
a plate reader (BioTek SynergyHT) equipped with an UV-Vis
absorption spectral detector. We plotted the OD600 nm of the cell
suspension over time to determine the time (18 h) for the
cultured cells to reach their conuence. Thus, we used the
OD600 nm of each cell suspension at 18 h to determine the
inhibitory effects of the free Ox and Ox nanocarriers (Fig. 6).
We also imaged the number and morphologies of single cells of
each cell suspension in amicrochamber using dark-eld optical
microcopy every 6 h over 18 h (Fig. 7).
Fig. 3 Characterization of the viability of the E. coli cells cultured in
the (A) standard and (B) modified LB medium using the live/dead
BacLight assay: (a) optical images and (b) fluorescence images of single
E. coli cells that were cultured in the medium over 18 h and charac-
terized by live/dead BacLight assay. The live cells emit the green
fluorescence (lmax¼ 525 nm) of SYTO9 and the dead cells emit the red
fluorescence (lmax ¼ 608 nm) of propidium iodide. (C) Plot of the
percentage of the live cells (number of live cells divided by the total
number of cells) cultured in the (a) standard and (b) modified LB
medium shows that more than 99% of the cells are viable, indicating
that the modified LB medium is well suitable for culturing the viable
cells. Minimum 900 cells for each medium were assayed. The scale
bars in (A and B) are 5 mm.
Fig. 4 Characterization of the efflux function of ABC transporters of
the E. coli cells cultured in the standard (A and C) and modified (B and
D) medium, and (A & B) in the presence of 25 mM orthovanadate
(inhibitor of ATPase) and (C & D) in the absence of the inhibitor. Time-
course fluorescence intensity of Hoechst 33342 (0.5 mM) incubated
with the cells (OD600 nm ¼ 0.1 in PBS buffer, pH 7.2): (A and B) in the
presence of 25 mM orthovanadate and (C and D) in the absence of the
inhibitor for the cells cultured the in standard (A & C) andmodified (B &
D) medium shows that the ABC transporters of the cells cultured in the
standard (A and C) andmodified (B andD)medium exhibit similar efflux
kinetics, which demonstrates that the modified LB medium is well
suitable to culture the cells for study of the efflux function of ABC
membrane transporters.


































































































TheMIC can be determined by culturing the bacterial cells in
the dilution series of antibiotics either in a liquid LB-medium or
on solid culture plates (CFU, a colony-forming unit). In this
study, we cultured the bacterial cells in the dilution series of
antibiotics in a liquid LB-medium, which enabled the nano-
carriers to be well dispersed and avoided the aggregation of
nanocarriers in solid culture plates. Furthermore, this enabled
us to characterize the stability of nanocarriers in the liquid
medium in real time at single NP resolution, and to determine
the MICs semi quantitatively by mathematically tting the
experimental data.
Data analysis and statistics
We characterized sizes and shapes of single Ag NPs using TEM,
and LSPR spectra of single Ag, AgMUNH2, and AgMUNH–Ox
NPs using DFOMS, as we reported previously.46 We imaged at
least 100 NPs for each measurement and repeated each exper-
iment three times for each individual size. Therefore,
a minimum of 300 NPs were characterized using TEM and
DFOMS. All the experiments were carried out in triplicate for
each concentration and each different sized antibiotic nano-
carriers. We used the average of three measurements with
standard deviations to characterize the size-dependent inhibi-
tory effects of nanocarriers on the cell growth.
Results and discussion
Antibiotic nanocarriers (AgMUNH–Ox NPs)
To study the dependence of inhibitory effects upon the bacterial
strains and enable us to compare this study with previous
studies, we used the same antibiotic nanocarriers as those that
we designed, synthesized and characterized in our previous
studies.45,46 We rst synthesized, puried and characterized
three different sized Ag NPs with diameters of 2.4  0.7, 13.0 
3.1 and 92.6  4.4 nm. We used the strong interaction of the
thiol of 11-amino-1-undecanethiol hydrochloride (MUNH2) with
the surface of Ag NPs to attach a self-assembled monolayer of
MUNH2 onto the NPs and to create AgMUNH2 NPs (Fig. 1).45,46
We then covalently linked the carboxyl group of Ox with the
amine group of MUNH2 on the NPs (AgMUNH2 NPs) using the
peptide bond to produce antibiotic nanocarriers (AgMUNH–
Ox NPs) (Fig. 1).45,46
We thoroughly washed the nanocarriers with DI water using
centrifugation to remove unattached antibiotics and chemicals
and to purify the nanocarriers. We characterized the sizes and
optical properties of the Ag NPs, AgMUNH2 NPs and AgMUNH–
Ox NPs using TEM, DLS and DFOMS. We quantitatively
Fig. 5 Study of dose and size dependent inhibitory effects of antibiotic
nanocarriers (AgMUNH–Oflx NPs) against the growth of the E. coli
cells. The cells were cultured in the modified medium containing: (A)
free Oflx alone at (a) 0 (blank control), (b) 0.045, (c) 0.09, (d) 0.18, (e)
0.38 and (f) 0.68 mM; (B–D) antibiotic nanocarriers of (B) 2.4  0.7, (C)
13.0  3.1 and (D) 92.6  4.4 nm with (a) 0 (AgMUNH2 NPs, without
Oflx), (b) 0.045, (c) 0.09, (d) 0.18, (e) 0.38 and (f) 0.68 mM Oflx. The
concentrations of AgMUNH2 NPs in (a) containing the same concen-
tration of the NPs as that of the highest concentration of each different
sized nanocarrier in ((f) in B–D): 0.79 nM, 7.2  102 nM and 1.0 pM
NPs, respectively.
Fig. 6 Quantitative analysis of size-dependent MIC50 of antibiotic
nanocarriers (AgMUNH–Oflx NPs) against the E. coli cells in Fig. 5.
Plots of normalized OD600 nm of the cells cultured for 18 h in the
modified medium containing (A–C) AgMUNH2 NPs (absence of Oflx,
control), (D) free Oflx alone, and (E–G) antibiotic nanocarriers of (E) 2.4
 0.7, (F) 13.0  3.1 and (G) 92.6  4.4 nm, versus (A–C) AgMUNH2 NP
concentration (control of the highest concentration of each different
sized nanocarrier), and (D–G) versus Oflx concentration. The
concentrations of AgMUNH2 NPs in (A–C) containing the same
concentration of the NPs as that of the highest concentration of each
different sized nanocarrier as 0.79 nM, 7.2  102 nM and 1.0 pM NPs
for 2.4  0.7, 13.0  3.1 and 92.6  4.4 nm nanocarriers, respectively.
The points are experimental data and each solid line is generated by
fitting of the experimental data with an equation (y ¼ aebx) as the
following: (D) y ¼ 1.12e5.57x, R2 ¼ 0.944; (E) y ¼ 1.12e2.56x, R2 ¼
0.928; (F) y ¼ 1.08e9.58x, R2 ¼ 0.941; and (G) y ¼ 1.01e26.7x, R2 ¼
0.988. Concentrations of Oflx (MIC50, IC50) for free Oflx and given
sized nanocarriers were determined using the exponential fitting
equation at the half of the maximum of the normalized OD600 nm,
respectively.


































































































determined the molar conjugation ratios of Ox molecules per
NP for 2.4  0.7, 13.0  3.1, and 92.6  4.4 nm NPs to be 8.6 
102, 9.4  103, and 6.5  105 using UV-Vis absorption spectra of
the plasmonic absorption of the given sized NPs and absorption
of Ox at 288 nm, respectively.46 We also characterized the zeta
potentials of Ag NPs, Ag MUNH2 NPs and AgMUNH–Ox NPs in
PBS buffer (pH 7.2) using a Nicomp 380ZLS particle sizing
system, as summarized in Table 1. The citrate molecules (pKa1
Fig. 7 Study of dependence of bactericidal inhibitory effects (morphology and length of single E. coli cells) of antibiotic nanocarriers upon their
sizes. Representative (a) dark-field optical images and (b) histograms of distribution of length of single cells that were cultured for 18 h in the
modified medium containing (A) 0 (blank control), (B) 0.045 mM free Oflx alone, and (C–E) 0.045 mM Oflx attached onto the NPs (antibiotic
nanocarriers) with diameters of: (C) 2.4 0.7, (D) 13.0 3.1 and (E) 92.6  4.4 nm, show the size-dependent bactericidal inhibitory effects of the
antibiotic nanocarriers and that the largest nanocarriers create the highest bactericidal inhibitory effects and generate the longest filamentation
and highest percentage of filamentous cells. The scale bars in (a) are 5 mm.


































































































¼ 3.31; pKa2 ¼ 4.76; pKa3 ¼ 6.39) adsorbed onto the NPs in the
PBS buffer (pH ¼ 7.2) lead to negatively charged Ag NPs. As
MUNH2 molecules replaced citrate molecules to attach onto the
surface of the NPs via the interaction of the –SH group with the
surface of Ag NPs, positively charged AgMUNH2 NPs were ob-
tained. The pKa1 and pKa2 of Ox were 5.97 and 9.28, respec-
tively.52 The carboxyl group of the Ox (pKa1) was covalently
linked with the amine group of MUNH2 attached on the NPs
(AgMUNH2 NPs). Thus, the amine group of Ox (pKa2 of Ox ¼
9.28) generated positively charged nanocarriers in the PBS
buffer (pH ¼ 7.2), as summarized in Table 1. The charges of the
nanocarriers increase with the size of the NPs unproportionally,
which is because the surface of the NPs (13.0  3.1 and 92.6 
4.4 nm) is not fully covered with Ox, as indicated by the
conjugation ratio of Ox molecules per NP.50
We characterized the stability (non-aggregation) of the
antibiotic nanocarriers with desired concentrations in
a commonly used standard LB medium (1% tryptone, 0.5%
yeast extract and 0.5% NaCl in DI water, pH¼ 7.2) in the shaker
(200 rpm, 37 C) over 12 h using DLS, UV-Vis spectroscopy and
DFOMS. We found that they were aggregated in the standard LB
medium, which would alter their sizes, lead to precipitation of
the nanocarriers and decrease their doses over time.46 There-
fore, we reduced NaCl concentration from 0.5% to 0.1%, and
designed a modied cell culture medium (1% tryptone, 0.5%
yeast extract and 0.1% NaCl in DI water, pH¼ 7.2), in which the
nanocarriers with desired concentrations were stable (non-
aggregated) over 24 h, under the cell culture conditions, in the
shaker (200 rpm, 37 C).
Viability and efflux function of cells cultured in the modied
medium
To characterize the suitability of the modied LB medium for
culturing the E. coli strain, we followed the cell growth and
determined the cell growth kinetics of the cultured cells in both
the standard LB medium and the modied LB medium over
time. The growth curves of the cells cultured in the standard LB
medium (Fig. 2A) and in the modied LB medium (Fig. 2B) over
time show the same growth kinetics, indicating that the cells
grew well in both mediums. We then characterized the viability
of the cells cultured in the standard and the modied medium
over 18 h using a live/dead BacLight assay.49 Representative
optical images of the cells cultured in the standard LB medium
(Fig. 3A) and the modied LB medium (Fig. 3B) show SYTO9
green uorescence but not propidium iodide red uorescence,
demonstrating that more than 99% of the cultured cells were
viable (Fig. 3C) and the modied LB medium can be used to
culture the cells.
Furthermore, we characterized the efflux functions of the
ABC membrane transporters of the live cells (E. coli) by
measuring the time-course intracellular uorescence intensity
of Hoechst dye (Hoechst 33342) in real time in the presence and
absence of the ATPase inhibitor (orthovanadate), which inhibits
ATPase and hydrolysis of ATP to ADP that powers the ABC
membrane transporters to extrude the substrates out of the
cells.53,54 Notably, the Hoechst dye emits weak uorescence in
aqueous solution and its uorescence quantum yield increases
substantially (up to 10 times) once it enters the cells and
intercalates with DNA.55 The Hoechst dye is a well-known
substrate of ABC membrane transporters and has been widely
used as an assay for real-time monitoring accumulation of the
intracellular dye molecules and for characterization of the efflux
kinetics of ABC membrane transporters of live cells.29,50,51
The time-course uorescence intensity of Hoechst dye
incubated with the cells that were cultured in the standard LB
medium (Fig. 4A) and the modied LB medium (Fig. 4B) in the
presence of the ATPase inhibitor (25 mM orthovanadate)53,54
shows similar accumulation kinetics of intracellular dye mole-
cules. The time-course uorescence intensity of the dye incu-
bated with the cells that were cultured in the standard LB
medium (Fig. 4C) and the modied LB medium (Fig. 4D) in the
absence of the ATPase inhibitor (control experiment) shows
similar accumulation kinetics of the intracellular dye molecules
in the cells cultured in both mediums. The result shows that the
uorescence intensity of the dye incubated with the cells
increases with time much more rapidly in the presence of the
inhibitor than in the absence of inhibitor, indicating that the
ABC transporters extrude the dye molecules out of the cells in
the absence of the inhibitor, which leads to the lower and slower
accumulation of intracellular dye molecules over time. Taken
together, the results in Fig. 2–4 demonstrate that the modied
LB medium is well suitable to culture the E. coli cells with well-
functional ABC membrane transporters.
Size and dose dependent inhibitory effects of antibiotic
nanocarriers
We quantitatively determined the size and dose dependent
inhibitory effects (MIC50) of Ox nanocarriers against the E. coli
cells. We cultured the cells (104 pre-cultured cells) in the
modied LB medium containing a dilution series of free Ox,
each given sized Ox nanocarriers (AgMUNH–Ox NPs) and the
corresponding size AgMUNH2 NPs (absence of Ox, control
experiment) under vigorous shaking (200 rpm, 37 C), and
measured the cell growth curves over 18 h. The dilution series
consist of (a) 0, (b) 0.045, (c) 0.09, (d) 0.18, (e) 0.38, and (f) 0.68
mM free Ox (Fig. 5A(a–f)) or Ox attached onto the nanocarriers
(Fig. 5B–D(a–f)), respectively. The nanocarriers correspond to
(Fig. 5B(a–f)): (a) 0.79 nM AgMUNH2 NPs (absence of Ox,
control), (b) 5.2  102, (c) 0.10, (d) 0.21, (e) 0.44, and (f) 0.79
nM 2.4  0.7 nm nanocarriers with a conjugation ratio of 8.6 
102 Ox molecules per NP; (Fig. 5C(a–f)): (a) 7.2  102 nM
Table 1 Characterization of zeta potentials of Ag, AgMUNH2, and
AgMUNH–Oflx NPs (nanocarriers) in the PBS buffer (pH ¼ 7.2)
Size (nm)
Zeta potentials (mV)
Ag NPs AgMUNH2 NPs AgMUNH–Ox NPs
2.4  0.7 21.38 2.35 2.11
13.0  3.1 33.52 8.82 7.57
92.6  4.4 55.16 21.26 18.14


































































































AgMUNH2 NPs (absence of Ox, control), (b) 4.8  103, (c) 9.5
 103, (d) 1.9  102, (e) 4.0 102, and (f) 7.2  102 nM 13.0
 3.1 nm nanocarriers with a conjugation ratio of 9.4  103 Ox
molecules per NP; (Fig. 5D(a–f)): (a) 1.0 pM AgMUNH2 NPs
(absence of Ox, control), (b) 6.9  102, (c) 0.14, (d) 0.28, (e)
0.58, and (f) 1.0 pM 92.6  4.4 nm nanocarriers with a conju-
gation ratio of 6.5  105 Ox molecules per NP. The cloudy
suspensions in Fig. 5 show that the bacterial cells grew, while
the clear suspensions indicate that the cell growth was signi-
cantly inhibited or the cells did not grow at all, suggesting high
dependence of inhibitory effects upon the dose of Ox and the
size of nanocarriers.
We quantitatively determined the concentration of the cells
over time by measuring their OD600 nm (optical density at 600
nm) at 6, 12 and 18 h. We subtracted OD600 nm of the nano-
carriers or AgMUNH2 NPs in the medium (in the absence of the
cells) from the OD600 nm of the cell suspension with the nano-
carriers or AgMUNH2 NPs, to determine the cell concentration,
respectively. The subtracted OD600 nm of the cell suspension at
18 h was plotted versus the concentration of free Ox or Ox
covalently conjugated with a given sized Ox nanocarrier to
quantitatively determine the MIC50 of Ox against the E. coli
(Fig. 6).
Control experiments (Fig. 6A–C) show that the OD600 nm of
the cell suspension incubated with each of the three different
sized AgMUNH2 NPs (absence of Ox, 2.4  0.7, 13.0  3.1 or
92.6  4.4 nm) was nearly independent of size and dose of the
NPs, and the cells grew normally as those cultured in the
medium alone, indicating that the AgMUNH2 NPs at the given
concentrations did not create signicant inhibitory effects
against the growth of the E. coli cells. Note that Ag NPs them-
selves have showed inhibitory effects against bacteria.26,32,56 The
biocompatibility of the functionalized Ag NPs (AgMUNH2 NPs)
could be attributed to the surface protecting layer of MUNH2
and the low concentration of AgMUNH2 NPs, as we reported
previously.33,40,57 At a low concentration, Ag NPs and function-
alized Ag NPs do not inhibit bacterial growth and can be used to
study the efflux function of single live bacterial cells.29–32,58,59
Further, our previous studies also show that the positively
charged peptide functionalized Ag NPs are more biocompatible
with the zebrash embryonic development than negatively
charged peptide functionalized Ag NPs.57
In contrast, the OD600 nm of the cell suspension incubated
with free Ox (Fig. 6D) or Ox attached onto the given sized
nanocarriers (Fig. 6E–G) decreases as Ox concentration
increases and as the size of the nanocarriers increases, showing
that inhibitory effects on the growth of E. coli cells highly
depend upon the dose of Ox and the size of nanocarriers. To
quantitatively determine MIC50, we t the experimental data
using an exponential decay equation (y ¼ aebx) with the
highest regression and lowest error via MatLab. The MIC50 of
Ox is dened as the concentration of Ox required to reduce
the growth of the cells by half. The results of MICs are
summarized in Table 2, showing that the MICs of free Ox and
Ox attached on nanocarriers highly depend upon the dose of
Ox and the size of nanocarriers.
For free Ox (Fig. 6D), the OD600 nm of the cell suspension
decreases with the increasing Ox concentration, showing the
MIC50 of 0.144  0.008 mM Ox against the E. coli cells. Inter-
estingly, the OD600 nm of the cell suspension cultured with 2.4
0.7 nm Ox nanocarriers (Fig. 6E) decreases with the increasing
Ox concentration less rapidly than that for free Ox and two
other larger nanocarriers, showing the highest MIC50 of 0.314
0.010 mM Ox and the lowest inhibitory effects against the E.
coli. Notably, the OD600 nm of the cell suspension cultured with
13.0  3.1 nm Ox nanocarriers (Fig. 6F) decreases with the
increasing Ox concentration more rapidly than that for free
Ox and 2.4  0.7 nm Ox nanocarriers, showing lower MIC50
of 0.081  0.002 and higher inhibitory effects against the E. coli
cells than those of free Ox and 2.4  0.7 nm Ox nanocarriers.
Further, the OD600 nm of the cell suspension cultured with 92.6
 4.4 nm nanocarriers (Fig. 6G) decreases with the increasing
Ox concentration most rapidly, showing the lowest MIC of
0.026  0.003 Ox and the highest inhibitory effects against the
E. coli cells.
It is worth noting that the MIC50 of Ox nanocarriers highly
depends upon their sizes. The largest size (92.6  4.4 nm)
nanocarriers exhibit the lowest MIC50 and the highest inhibi-
tory effects among the nanocarriers and free Ox. In other
words, the same amount of Ox molecules loaded and delivered
via the largest NPs (92.6  4.4 nm) is the most potent, followed
by 13.0  3.1 nm nanocarriers, free Ox, and 2.4  0.7 nm
nanocarriers (Table 2). TheMIC50 of conjugated Ox of 2.4 0.7
nm nanocarriers is more than two times higher than that of free
drug Ox. In contrast, the MIC50 of 13.0 3.1 nm and 92.6 4.4
nm nanocarriers is nearly two times and 6 times lower than that
of free Ox, respectively. The highest number of Ox molecules
attached onto the largest nanocarriers could behave similarly to
a planar surface (low particle curvature) leading to a larger
contact surface area to create a high local concentration, which
consequently favors formation of more drug binding sites.60,61
These ndings suggest that the densely packed Ox molecules
that are covalently linked with the self-assembled monolayer of
MUNH2 on the surface of the NPs could create multi-valence
effects and enhance binding affinity of Ox with target mole-
cules and increase inhibitory effects.62,63 Notably, the size-
dependent inhibitory effects (MIC50) of the nanocarriers are not
Table 2 Study of dependence of MIC50 of Oflx upon the size of
nanocarriers in E. coli (WT)
Samples MIC50 of Ox
a (mM)
Free Ox alone 0.144  0.008
Nanocarriers (2.4  0.7 nm) 0.314  0.010
Nanocarriers (13.0  3.1 nm) 0.081  0.002
Nanocarriers (92.6  4.4 nm) 0.026  0.003
a The MIC of Ox for each sample was determined by tting the
experimental data with the exponential decay (y ¼ aebx, inhibitory
effects upon the exponential cell growth) to determine the parameters
(a and b) of a tting equation with a regression using MatLab. The
equation was then used to determine the concentration of Ox at
which the cell growth was inhibited to the half of the cell growth of
the blank control experiment, as described in Fig. 6 caption.


































































































linearly proportional to their sizes, suggesting that it might have
a trade-off role in inhibitory effects between the distribution of
the same amount of the Ox molecules throughout the cells and
concentrating them on individual nanocarriers locally. Free Ox
and Ox on smaller nanocarriers (2.4  0.7 nm) might be
distributed inside the cells more uniformly than the Ox
attached onto the larger nanocarriers (13.0 3.1 nm and 92.6
4.4 nm), while the larger nanocarriers offer higher local Ox
concentration and higher binding affinity with the target sites
than the smaller nanocarriers. Considering the combination of
Ox distribution and binding affinity, an optimal size of
nanocarriers could be designed to achieve the maximum anti-
biotic potency against given bacterial cells.
Size-dependent lamentation of E. coli using single live cell
imaging
To investigate the mode of action of Ox nanocarriers, we
imaged the cells that had been cultured with free Ox and Ox
nanocarriers over 18 h using dark-eld optical microscopy.
Representative optical images of the cells (Fig. 7B) incubated
with (A) 0, (B) 0.045 mM free Ox and 0.045 mM Ox attached
onto the nanocarriers with diameters of NPs of (C) 2.4 0.7, (D)
13.0 3.1 and (E) 92.6 4.4 nm show that in the absence of Ox
(medium alone or AgMUNH2 NPs), the E. coli cells grew nor-
mally and the average length of the cells was 1.8  0.4 mm and
no lamentous cells were observed (Fig. 7A), while the cells
became lamentous in the presence of 0.045 mM free Ox and
Ox nanocarriers (Fig. 7B–E). The percentage and length of
lamentous cells highly depended upon the MIC50 of Ox and
the size of the nanocarriers. 0.045 mM free Ox generated 14.9%
lamentous cells with an average length of cells at 3.8 3.4 mm,
ranging from 1.0 to 28.6 mm (Fig. 7B). Notably, the 0.045 mMOx
nanocarriers of 2.4 0.7, 13.0 3.1 and 92.6 4.4 nm (Fig. 7C–
E) generated (C) 1.2% lamentous cells with an average length
of 2.0  0.9 mm, ranging from 1.1 to 11.4 mm; (D) 35% la-
mentous cells with an average length of 7.2  8.7 mm, ranging
from 1.4 to 57.0 mm; (E) 59% lamentous cells with an average
length of 12.2  12.1 mm, ranging from 1.7 to 73.8 mm,
respectively. The results further demonstrate that the larger
nanocarriers showed higher inhibitory effects and generated
longer and a higher percentage of lamentous cells than the
smaller nanocarriers. Interestingly, 2.4  0.7 nm Ox nano-
carriers exhibited less inhibitory effect against the cells than
free Ox, and produced shorter and a lower percentage of la-
mentous cells than free Ox, which is consistent with their
MIC50 in Fig. 5 and 6. Notably, the cells cultured with the largest
nanocarriers (92.6 4.4 nm) with the Ox concentration higher
than 0.045 mM did not grow and did not create a sufficient
number of cells for statistics analysis.
Ox is a uoroquinolone antibiotic and has been commonly
used to treat skin, bladder and urinary tract infection.66,67 Its
molecular target is DNA gyrase which is a crucial bacterial
enzyme that catalyzes the negative supercoiling of double
stranded DNA during cell replication.66 Notably, Ox can also
partially inactivate D-alanine carboxypeptidases (enzymes that
regulate the extent of peptide side-chain cross-linking in
peptidoglycan) and interfere with peptidoglycan biosynthesis,
and bacterial lamentation in E. coli.68–70 Notably, b-lactam
antibiotics (e.g., penicillin) and bacteriostatic antibiotics (e.g.,
chloramphenicol) can generate lamentous cells.71,72
New ndings
Our previous studies show the dose and size dependent inhib-
itory effects of antibiotic nanocarriers (AgMUNH–Ox NPs)
against Pseudomonas aeruginosa (Gram-negative bacterium) and
Bacillus subtilis (Gram-positive bacterium).45,46 Interestingly,
inhibitory effects of antibiotic nanocarriers highly depend upon
the expression of MexAB-OprM (multidrug membrane trans-
porter) in Pseudomonas aeruginosa,46 but not the expression of
BmrA (multidrug ABC membrane transporter) in Bacillus sub-
tilis.45 This study shows that the inhibitory effects of nano-
carriers against E. coli (Gram-negative bacterium) highly
depend upon the dose and size of nanocarriers and the efflux
function of ABC transporters in E. coli. This study shows that the
mode of action of nanocarriers against E. coli is bactericidal
effects that cause cellular lamentation, which highly depends
upon the dose and size of nanocarriers. Notably, we did not
observe any cell lamentation when Pseudomonas aeruginosa or
Bacillus subtilis cells were cultured with the nanocarriers, as we
reported previously.45,46 These ndings indicate that the modes
of action of Ox nanocarriers could highly depend upon the
sizes of nanocarriers and the bacterial strain.
Notably, the MIC50 values of free Ox and the Ox nano-
carriers (2.4  0.7, 13.0  3.1 and 92.6  4.4 nm) against E. coli
are 4, 3, 5, and 4 lower than those against P. aeruginosa
(WT), respectively.46 Interestingly, the MIC50 values of free Ox
and Ox attached on nanocarriers (2.4  0.7 nm) against E. coli
are nearly the same as those against BmrA (WT, B. subtilis),45
while the MIC50 values of Ox nanocarriers (13.0  3.1 and 92.6
 4.4 nm) against E. coli are two times lower and two times
higher than those against BmrA (WT, B. subtilis), respectively.
The dose and size dependent inhibitory effects of Ox nano-
carriers against bacterial strains could be attributed to the
combination of several factors such as their permeability into
the bacterial cells and the efflux function of membrane trans-
porters in extruding nanocarriers out of cells.22,64 We have
observed Ox nanocarriers inside the cells and have used Ox
nanocarriers to study the efflux function of ABC transporters in
single live cells.65 Further studies are needed to depict the
underlying molecular mechanisms. These new ndings
demonstrate the importance of using the same nanocarriers
and same experimental methods to study their effects on
different bacterial strains in order to determine the dependence
of effects of nanocarriers against different membrane trans-
porters and different bacterial strains. We cannot extrapolate
these new ndings from the previous studies.
Summary
In summary, we have successfully characterized and used three
different sized antibiotic (Ox) nanocarriers to study their dose
and size-dependent inhibitory effects against E. coli. We have


































































































designed a modied LB medium to culture the cells and enable
the nanocarriers with desired concentrations to be stable (non-
aggregated) in the medium over time (18 h) during the cell
culture. Therefore, the dose and size of the nanocarriers remain
unchanged over time, which enables us to study their dose and
size dependent inhibitory effects against the E. coli cells and
compare these new ndings with those from our previous
studies.45,46 We found that the inhibitory effects of Ox nano-
carriers against the E. coli increase as the dose of Ox and the
size of nanocarriers increase. The largest nanocarriers (92.6 
4.4 nm) show the highest inhibitory effect and the lowest MIC50
(0.026  0.003 mM) while the smallest nanocarriers (2.4  0.7
nm) exhibit the lowest inhibitory effect and the highest MIC50
(0.314  0.010 mM) against E. coli. These results demonstrate
that inhibitory potency of the same amount of Ox molecules
could substantially increase when they are carried and delivered
by the larger nanocarriers, suggesting that the densely packed
Ox molecules on the NPs might have offered multivalence
effects, which augments the binding affinity and increases local
drug concentrations, leading to higher potency. Further, our
results show the size-dependent effect of Ox nanocarriers on
cellular lamentation, leading to bacterial death, and that the
larger nanocarriers create longer and higher percentage of
lamentous cells than the smaller nanocarriers. Notably, the
inhibitory effect and bactericidal effect of the smallest nano-
carriers (2.4  0.7 nm) are less than free Ox, suggesting that
the combination of the multivalence effect and their intracel-
lular distribution could both play roles in their inhibitory effects
against the cell growth. These results show that the inhibitory
effects of nanocarriers are not linearly proportional to their
sizes, and the optimal-sized nanocarriers could be designed to
create the most potent effect of antibiotic nanocarriers. Efforts
are in progress to further characterize the underlying molecular
mechanisms of size-dependent inhibitory effects of nano-
carriers against bacteria.
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